Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1756-185X.70044 | DOI Listing |
Breast Cancer Res Treat
January 2025
Division of Medical Oncology, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, 8700 Beverly Blvd., Los Angeles, CA, 90048, USA.
Purpose: There is an increasing incidence of young breast cancer (YBC) patients with uncertainty surrounding the factors and patterns that are contributing.
Methods: We obtained characteristics and survival data from 206,156 YBC patients (≤ 40 years of age) diagnosed between 2005 and 2019 from the National Cancer Database (NCDB). Patients were subdivided into two comparison groups based on year of diagnosis (2005-2009, Old vs.
Crit Rev Anal Chem
January 2025
Chemistry Department, Faculty of Science, Cairo University, Giza, Egypt.
Epilepsy is a serious neurological disease that impacts all facets of a patient's life, including their socioeconomic situation. The failure to identify underlying epileptic signatures in their early stages might result in severe harm to the central nervous system (CNS) and permanent adverse changes to some organs. Therefore, numerous antiepileptic drugs (AEDs are frequently used to control and treat the frequency of seizures.
View Article and Find Full Text PDFAm J Sports Med
January 2025
Section of Young Adult Hip Surgery, Division of Sports Medicine, Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA.
Background: Many studies have examined the prevalence of acetabular version (AV) and femoral version (FV) abnormalities and their effect on patient-reported outcomes (PROs) after hip arthroscopy for femoroacetabular impingement syndrome (FAIS), but few have explored the prevalence and influence of combined version (CV) abnormalities.
Purpose: To (1) describe the distribution of AV, FV, and CV in the largest cohort to date and (2) determine the relationship between AV, FV, and CV and PROs after hip arthroscopy for FAIS.
Study Design: Cohort study; Level of evidence, 3.
Rheumatol Ther
January 2025
Biosplice Therapeutics, Inc., 9360 Towne Centre Dr, San Diego, CA, 92121, USA.
Introduction: Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. The objective of this trial was to evaluate long-term safety of LOR within an observational extension of two phase 2 trials.
Methods: This 60-month, observational extension study (NCT02951026) of a 12-month phase 2a trial (NCT02536833) and 6-month phase 2b trial (NCT03122860) was administratively closed after 36 months as data inferences became limited.
Sci Rep
January 2025
Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Nagyerdei blvd. 98, Debrecen, 4012, Hungary.
This prospective cohort study is aimed to investigate circadian variations in corneal parameters, focusing on sleep-deprived subjects. Sixty-four healthy individuals (age range: 21-76 years) actively participated in this study, undergoing examinations at least five times within a 24-hour timeframe. The analysis encompassed keratometric parameters of the cornea's front (F) and back (B) surfaces, refractive power in flattest and steepest axes (K1, K2), astigmatism (Astig) and its axis (Axis), aspheric coefficient (Asph), corneal pachymetry values of thinnest corneal thickness (Pachy Min) and corneal thickness in the center of the pupil (Pachy Pupil), volume relative to the 3 and 10 mm corneal diagonal (Vol D3, Vol D10) and surface variance index (ISV).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!